ArticleJournal, genetic engineering & biotechnology2025
Analytical and biological assessment of Magnolia champaca L. stem bark: Integrating ATR-FTIR, GC-MS, thrombolytic activity, brine shrimp lethality and molecular docking.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Magnorolins A-L: sesquiterpenoids with diverse skeletons from the fruits ofRSC advances · 2026Article
- From Reshaped Metabolome to Repaired Skin: FermentedAntioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer and cardiovascular disease are two of the most significant health challenges worldwide. These diseases are responsible for morbidity and mortality, leading to a substantial burden on healthcare systems and economic resources. Numerous innovative therapies have been proposed for combating cancer and cardiovascular disease like thrombosis; however, many of these treatments involve synthetic drugs that may have undesirable side effects. Consequently, the current research aimed to explore the medicinal properties of phytochemicals derived from Magnolia champaca L. This investigation utilized both in vitro and in silico approaches. The identification of phytocompounds were employed by using ATR-FTIR and GC-MS. Thrombolytic activity was assayed using human venous blood and cytotoxicity was assessed through lethality test using nauplii of Artemia salina and finally the molecular docking analysis was performed using a docking software named AutoDock Vina to clearly understand about the interactions of GC-MS identified secondary metabolites with target proteins. The ATR-FTIR spectrum of Magnolia champaca specifies the presence of some alkaloids, polysaccharides, flavonoids as well as glycosidic phytocompounds and GC-MS data identified 23 compounds from crude methanolic extract and among them 2,4-Di-tert-butylphenol; 3-Ethyl-3-hydroxyandrostan-17-one; Hexadecanoic acid, methyl ester; Di-n-octyl phthalate were prominent. The in vitro thrombolytic assay demonstrated that Trans-Syringin and CHF resulted in significant blood clot lysis, achieving 59.39 ± 1.79 % and 45.66 ± 3.63 % respectively comparing 75.75 ± 2.96 % with standard streptokinase. The brine shrimp bioassay indicated moderate to strong toxicological effect. Specifically, Trans-Syringin and the ethyl acetate fraction (EAF) demonstrated considerable cytotoxicity, showing the net values of LC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.